Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May-Jun;51(3):e20259904.
doi: 10.1590/S1677-5538.IBJU.2025.9904.

Management of Adverse Effects in Testosterone Replacement Therapy

Affiliations
Review

Management of Adverse Effects in Testosterone Replacement Therapy

Basheer Basheer et al. Int Braz J Urol. 2025 May-Jun.

Abstract

Purpose: This narrative review aims to provide the most updated knowledge regarding the treatment of adverse effects secondary to testosterone replacement therapy (TRT), such as gynecomastia, cardiovascular and hematologic risks, prostate health risk, and liver dysfunction risks.

Materials and methods: An extensive literature review was conducted, incorporating guidelines from the American Urological Association and the Endocrine Society. The studies determined common adverse effects and their most common methods of management.

Results: TRT improves the quality of life, sexual function, and mood in hypogonadal men. Possible adverse effects associated with TRT include increased estrogen levels and gynecomastia, which are usually managed with aromatase inhibitors and tamoxifen. Cardiovascular risks from TRT include hypertension and erythrocytosis, which mandate periodic hematocrit and blood pressure monitoring; therapeutic phlebotomy is indicated if the hematocrit exceeds 52%. No significant concern regarding prostate cancer has been observed in the closely monitored patient. However, TRT should not be administered to individuals with active evidence of untreated prostate cancer, except under rare circumstances such as active surveillance for very low-risk disease. Older oral forms of TRT can affect liver function; therefore, transdermal, newer oral forms and injectables are generally favored in men with a history of liver disease.

Conclusions: Monitoring and management of adverse effects are critical to maximize benefit and minimize the risks of TRT. Ongoing research will further elucidate the safety of TRT while advancing evidence-based practices in managing its associated adverse effects. Effective patient education and counseling are also essential to improve compliance and treatment outcomes.

Keywords: Testosterone; adverse effects [Subheading]; therapy [Subheading].

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1
Figure 1. Treatment algorithm of complications after testosterone replacement therapy.

References

    1. Lunenfeld B, Mskhalaya G, Zitzmann M, Corona G, Arver S, Kalinchenko S, et al. Recommendations on the diagnosis, treatment and monitoring of testosterone deficiency in men. Aging Male. 2021;24:119–138. doi: 10.1080/13685538.2021.1962840. - DOI - PubMed
    1. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536–2559. doi: 10.1210/jc.2009-2354. Erratum in: J Clin Endocrinol Metab. 2021 Jun 16;106(7):e2848. 10.1210/clinem/dgab311. - DOI - PubMed
    1. Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200:423–432. doi: 10.1016/j.juro.2018.03.115. - DOI - PubMed
    1. Marquardt NF, Filho, Da Ros CT. Can we recommend varicocele surgery for men with hypogonadism? Int Braz J Urol. 2023;49:637–643. doi: 10.1590/S1677-5538.IBJU.2023.0190. - DOI - PMC - PubMed
    1. Da Ros CT, Da Ros LU, Da Ros JPU. The role of clomiphene citrate in late onset male hypogonadism. Int Braz J Urol. 2022;48:850–856. doi: 10.1590/S1677-5538.IBJU.2021.0724. - DOI - PMC - PubMed